Navigation Links
NIH-funded scientists identify potential malaria drug candidates
Date:11/17/2011

Researchers have discovered a group of chemical compounds that might one day be developed into drugs that can treat malaria infection in both the liver and the bloodstream. The study, which appears in the Nov. 18 issue of Science, was led by Elizabeth A. Winzeler, Ph.D., of the Scripps Research Institute in La Jolla, Calif., and was partially funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Caused by four related parasites in the genus Plasmodium, malaria is transmitted to humans via the bite of an infected mosquito. Once the bite occurs, the parasites travel to the liver, where they usually multiply rapidly for about a week without causing symptoms. Symptoms begin when the parasites spread from the liver to the rest of the body through the bloodstream. However, the parasites can lay dormant in the liver for periods ranging from several months to years before an infected person demonstrates symptoms.

Most of the malaria drugs currently in development target the symptomatic, blood stage of infection. To help achieve malaria eradication, however, a drug would ideally treat infection during both the liver and blood stages. Currently, the World Health Organization recommends only one treatment, primaquine, for the initial, liver stage of certain types of malaria infection; however, primaquine and related drugs can cause a dangerous blood disorder among patients with a genetic condition that is common in malaria-endemic regions of the world. Additionally, drug resistance has been reported, which amplifies the need to find new treatment alternatives.

By screening more than 4,000 chemical compounds that had previously shown activity against blood-stage Plasmodium, the investigators searched for a compound that would also inhibit liver-stage parasites and whose protein structure would allow the modification necessary for future drug development. They found that a group of three related compounds, known collectively as the imidazolopiperazine (IP) cluster, fit these criteria. In addition, strains of Plasmodium that had acquired resistance to other malaria drugs were susceptible to the IP cluster.

Using the IP cluster as a foundation, the researchers designed a drug candidate, GNF179, that reduced levels of one Plasmodium species by 99.7 percent and extended survival by an average of 19 days when tested in malaria-infected mice. By examining infected cells, the researchers confirmed that GNF179 was active in the liver stage of infection. The researchers note that while additional studies will be needed to fully understand the drug's mechanism of action and its specific targets within the liver, this study provides a potential starting point for developing new dual-stage antimalarial drugs.


'/>"/>

Contact: Nalini Padmanabhan
padmanabhannm@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. NIH-funded scientists find 2009 H1N1 pandemic influenza vaccine protects mice from 1918 flu virus
2. University of Mississippi Medical Center to lead in nationwide NIH-funded Alzheimers study
3. NIH-funded study finds early HAART during TB treatment boosts survival rate in co-infected people
4. In NIH-funded study, researchers uncover step in brain events leading up to addiction
5. NIH-funded study uses new technology to peek deep into the brain
6. NIH-funded study finds new possible risk factor of heart disease
7. NIH-funded researchers find new ways to confuse blood-seeking mosquitoes
8. Traumatic brain injury: NIH-funded researchers will assess biomarkers for diagnosis and treatment
9. NIH-funded research points to potential therapy for tumor-associated epilepsy
10. NIH-funded twin study finds occupational chemical exposure may be linked to Parkinsons risk
11. Scientists Pinpoint Area of Brain That Fears Losing Money
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... TopConsumerReviews.com recently gave a best-in-class 5 star rating ... Scooters give freedom to people who need help getting around. For some, advancing age ... long period of rehabilitation after an illness or accident. There is a wide variety ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... magazine’s 2017 Training Top 125 for their industry leading training methods that engage ... recognizes USA as among the global elite in employer-sponsored training and development programs. ...
(Date:12/5/2016)... ... 2016 , ... Edward Buckingham MD , and the ... the newest Sciton laser in January 2017. The Halo is the first and ... wavelengths for exceptional results. Outperforming more traditional lasers, the innovative Halo automatically customizes ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... announced it has been featured in SuperbCrew magazine, a leading online tech news ... world. This interview, now featured on SuperbCrew.com, explores the state of enterprise mobility ...
(Date:12/5/2016)... Novato, CA (PRWEB) , ... December 05, 2016 ... ... company, has extended its partnership with leading global lifestyle design firm kathy ireland® ... , Worldwise® and kathy ireland® Worldwide entered into an exclusive licensing agreement three ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016 Sanovas, Inc., ... accelerator, announced today the launch of its wholly owned subsidiary, ... Logo - http://photos.prnewswire.com/prnh/20161202/445250LOGO   Logo - http://photos.prnewswire.com/prnh/20161202/445251LOGO   ... ... There are ...
(Date:12/5/2016)... -- Wellbridge Health and Gateway Health proudly announce a dynamic collaboration ... Medicaid plan members with specific high risk needs. ... this group of consumers, Wellbridge combines technology and population expertise ... into members, daily behaviors and lifestyle. ... , , ...
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
Breaking Medicine Technology: